Good morning, everyone, and how are you today? We are just fine, thank you, especially since the Pharmalot campus is unusually quiet this morning, since the short person is elsewhere, enjoying a mini-break from the local schoolhouse. As for us, we are pursuing our usual routine and relying on cups of stimulation for assistance. In the interest of full disclosure, our choice is apple cider donut. Feel free to join us. Meanwhile, there is much to do and, no doubt, you can relate. This is a busy time, yes? So here are some tidbits.

President Trump is expected to name former Eli Lilly (LLY) executive Alex Azar to lead the Department of Health and Human Services, according to various reports. Azar, who worked at the drug maker for much of the past decade, was president of Lilly U.S. operations until earlier this year, and served as HHS Deputy Secretary under former President George W. Bush.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy